Levothyroxine and a GLP-1: Why Your Thyroid Dose May Need to Come Down

Yes, levothyroxine and a GLP‑1 can be taken together, and an underactive thyroid is not on any GLP‑1 label as a reason to avoid one. There are two things to know. The semaglutide tablets — Rybelsus, Ozempic tablets and the Wegovy pill — raised thyroxine exposure by 33% in a dedicated study, and their labels say to consider closer monitoring.^[1] And over the following months, losing weight lowers the dose of levothyroxine most people need.^[10] Both effects push in the same direction on an unchanged dose: toward too much thyroid hormone, which shows up as a falling TSH, not a rising one.

What each GLP-1 label says about levothyroxine

Only the semaglutide tablets name levothyroxine. Every other label carries a general line about slowed stomach emptying and oral medicines, and none reports a levothyroxine study.

The semaglutide tablet study: a 33% rise

Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study. When using RYBELSUS or OZEMPIC tablets concomitantly with other oral drugs that have a narrow therapeutic index or that require clinical monitoring, consider increased clinical or laboratory monitoring.

— RYBELSUS and OZEMPIC tablets prescribing information, section 7.2

The figure comes from a single trial. Forty-five healthy volunteers took one large dose of levothyroxine (600 mcg) on its own, and again once they had reached steady state on 14 mg of oral semaglutide. Total thyroxine exposure, corrected for the hormone the body makes itself, was 33% higher with semaglutide on board. The peak level did not change — the extra exposure came from the thyroxine staying around longer, not from a higher spike.^[3][1] The authors concluded that monitoring of thyroid parameters should be considered when the two are used together.^[3]

The Wegovy label, which covers both the injection and the pill, repeats the 33% figure for the tablet and tells prescribers to monitor oral medicines taken alongside it.^[2] Ozempic tablets, a newer semaglutide tablet, share Rybelsus’s label; the two are not interchangeable milligram for milligram, but the levothyroxine warning on that label applies to both.^[1]

Why the tablet does this is not established. The tablet contains an absorption enhancer called SNAC, and the trial tested it separately: SNAC alone did not change total thyroxine exposure.^[3] The label puts it under the general heading that semaglutide slows stomach emptying and so can affect how other oral drugs are absorbed.^[1] For a reader, the mechanism matters less than the direction, and the direction is more thyroxine.

Ozempic and Wegovy injections: no levothyroxine study

The 33% is a tablet finding, and it should not be carried over to the weekly injection. The Wegovy label says plainly that in pharmacology trials with the 1 mg semaglutide injection, semaglutide left the absorption of the oral medicines tested unchanged.^[2] The Ozempic injection label says the same, with the qualifier “to any clinically relevant degree”, but the drugs it tested were metformin, an oral contraceptive, warfarin, digoxin and atorvastatin. Levothyroxine was not one of them, and the label still asks for caution with oral medicines because the injection slows stomach emptying.^[4]

The tirzepatide labels, Mounjaro and Zepbound, go a step further than Ozempic’s. They ask prescribers to monitor people on oral drugs that depend on reaching a threshold level and those with a narrow therapeutic index, using warfarin as the example.^[5][6] Levothyroxine fits that description: Synthroid’s own label says it has a narrow therapeutic index, and that both too much and too little can harm the heart, bones and metabolism.^[8] Foundayo, the daily orforglipron tablet, carries the general gastric-emptying caution and notes that the slowing peaks after the first dose and fades over time; it reports no levothyroxine study.^[7] More on Foundayo is in our Foundayo evidence review.

The slower effect: weight loss lowers the dose you need

The interaction study looks at a single day. The change that matters more for most people on a weight-loss dose plays out over months. Synthroid’s label gives the full adult replacement dose as 1.6 mcg per kilogram per day and lists body weight among the factors that set the dose.^[8] More precisely, the need tracks lean body mass rather than fat: in a study of 75 patients, the levothyroxine dose correlated far more strongly with lean mass than with fat mass.^[9]

The best data on what happens after large weight loss come from bariatric surgery, because no study has yet followed levothyroxine doses through a full course of a GLP‑1. Those data agree on the direction for most people and show where the exceptions come from.

Read together, the studies say the daily dose usually comes down, but by less than the weight does.^[10][11][12] The Italian group found the reduction was proportional to the lean mass lost, which is a smaller share than total weight.^[10] Gastric bypass adds a separate problem — it cuts out part of the gut where tablets are absorbed — and that is why the per-kilogram dose rose most after bypass.^[12] A GLP‑1 does not reroute the gut, so that particular push in the other direction does not apply.

The published GLP‑1 cases all run that way. A woman with no thyroid after surgery, stable on levothyroxine for five years, had a suppressed TSH after starting semaglutide injections and needed her dose cut by 25%.^[13] Another, also after thyroidectomy, lost 48 pounds over six months on tirzepatide and arrived with dizziness, a racing heart and confusion; her TSH was markedly suppressed and free T4 raised.^[14] A third developed palpitations as she lost weight on semaglutide, and her thyroid tests showed too much hormone until the dose was lowered.^[15] These are case reports: they show what the path looks like, not how often it happens. People with no thyroid tissue of their own have no reserve to buffer a change, which is why both thyroidectomy cases were striking.^[14]

Taking a semaglutide tablet and levothyroxine in the same morning

Both drugs are meant for an empty stomach at the start of the day, and their labels were not written with each other in mind.

Followed literally, the tablet’s rule says nothing else by mouth for 30 minutes, and levothyroxine’s says nothing to eat for 30 to 60 minutes after it.^[1][2][8] The labels do not say which should come first or whether they can share a glass of water, and in the interaction study the two were taken together — which is the situation the 33% describes.^[3] The tablet labels also matter for the semaglutide side: in the same trial, swallowing five extra placebo tablets alongside oral semaglutide cut semaglutide exposure by 34%.^[3]

Whatever routine your prescriber or pharmacist settles on, the point the Synthroid label makes is consistency: it asks prescribers to reconsider the dose when levothyroxine is regularly taken within an hour of certain foods, because absorption depends on how it is taken.^[8] A dose that was set while you took levothyroxine alone may land differently once a semaglutide tablet shares the morning, which is the reason the label calls for monitoring. A weekly injection or Foundayo, which can be taken with or without food, does not create this timing clash.^[4][5][7] The broader picture of GLP‑1s and other oral drugs is in GLP-1 drugs and your other medications.

When to recheck TSH

The Synthroid label sets the schedule a prescriber works from. After any change in levothyroxine dose, check TSH again after 6 to 8 weeks. On a stable dose, check every 6 to 12 months — and whenever the patient’s clinical status changes.^[8] Starting a GLP‑1 and losing a meaningful amount of weight is that kind of change. The bariatric researchers advised against cutting the dose in advance and in favor of checking TSH and thyroid hormones periodically as weight falls, then adjusting.^[10]

In practice, that recheck often does not happen. Among 5,370 matched Medicare patients on stable levothyroxine, about 83% had a TSH test within a year whether they started a GLP‑1 or an SGLT2 inhibitor, at a mean of about 130 days in both groups — no faster for the drug that removes more weight.^[16] That gap is the subject of the thyroid test nobody reordered. If you take biotin, a common hair-loss supplement, the Synthroid label says to stop it at least 2 days before the blood test, because it can distort the result.^[8]

It also helps to know what too much levothyroxine feels like, because much of it overlaps with what people put down to the GLP‑1. Synthroid’s label lists palpitations and a fast heart rate, anxiety, insomnia, tremor, heat intolerance, sweating, fatigue and weight loss among the effects of over-replacement.^[8] A racing heart on a GLP‑1 has several possible causes, worked through in GLP-1 drugs, heart rate and palpitations.

Hypothyroidism is not a reason to avoid a GLP-1

An underactive thyroid treated with levothyroxine does not appear among the contraindications on any GLP‑1 label. The thyroid line that is on every label is the boxed warning about medullary thyroid carcinoma: each label makes the drug off-limits for anyone who has had that cancer or has a relative who did, and for anyone who carries the inherited syndrome multiple endocrine neoplasia type 2, known as MEN 2.^[1] That is a rare cancer of the thyroid’s C-cells, a different cell type and a different disease from the common causes of hypothyroidism. What that warning rests on is covered in GLP-1 drugs and thyroid cancer risk.

One thing does run the other way. Synthroid carries its own boxed warning: thyroid hormone must not be used to treat obesity or for weight loss. In people with normal thyroid function, ordinary doses do not cause weight loss, and larger doses can cause serious or life-threatening toxicity.^[8] Weight loss is the GLP‑1’s job; the levothyroxine dose follows the body you have, not the one you are aiming for.